Abstract
Cancer cachexia is a devastating multifactorial syndrome characterized by progressive skeletal muscle wasting, which significantly impacts patient survival and quality of life. This study investigated the therapeutic potential of aliskiren, a small-molecule renin inhibitor, in a C26 mouse colon carcinoma model of cancer cachexia. Aliskiren was administered to BALB/c mice either as a preventive strategy (AP group, starting day 5 post-injection) or a therapeutic strategy (AT group, starting day 12). The study found that aliskiren significantly alleviated multiple cachexia-associated symptoms, including body weight loss, tumor burden, muscle wasting, and muscular dysfunction, while extending overall survival. Mechanistically, aliskiren inhibited the renin-angiotensin system (RAS), systemic and muscular inflammation, oxidative stress, and the activation of the autophagy-lysosome (ALP) and ubiquitin-proteasome (UPP) pathways. Notably, early preventive administration yielded more robust results than later therapeutic intervention, suggesting the importance of early clinical management.
Introduction
Cancer cachexia affects up to 80% of patients with advanced malignancies and is responsible for approximately 30% of all cancer-related deaths. It is not merely weight loss but a complex metabolic breakdown characterized by the loss of skeletal muscle mass. Currently, there are no highly effective treatments for this syndrome. While the Renin-Angiotensin System (RAS) is widely recognized for its role in blood pressure regulation, recent evidence suggests that local RAS activation in muscle tissue promotes protein degradation and inhibits synthesis. This study explores whether aliskiren—a direct renin inhibitor—can be repurposed to intercept these pathological pathways and preserve muscle mass and function in the context of cancer.
Methods
The study employed a well-established cancer cachexia model using C26 mouse colon carcinoma cells injected subcutaneously into isogenic BALB/c mice. Researchers tested two intervention windows: a prevention group (AP), where aliskiren (10 mg/kg) was administered on Day 5 when tumors were first palpable, and a treatment group (AT), where administration began on Day 12 after cachexia symptoms were established. Control groups included healthy mice (HC) and untreated cancer-bearing mice (CA).
A multi-modal assessment strategy was used to evaluate the drug's efficacy:
- Functional Testing: Grip strength and rotarod tests were used to measure muscular coordination and endurance.
- Molecular Profiling: qPCR and Western Blotting tracked markers of the Autophagy-Lysosome Pathway (ALP), such as Bnip3 and Beclin1, and the Ubiquitin-Proteasome Pathway (UPP), including Atrogin1 and MuRF1.
- Biochemical Assays: ELISA measured inflammatory cytokines (TNF-α, IL-6), and specific assays quantified oxidative stress markers like Superoxide Dismutase (SOD), Malondialdehyde (MDA), and hydroxyl radicals.
- Histology: Muscle fiber cross-sectional areas were measured in the gastrocnemius muscle to quantify wasting.
Results
Aliskiren treatment led to significant improvements across all primary phenotypic and molecular markers of cachexia.
Body Mass and Tumor Burden
The untreated cancer group (CA) experienced a profound 32.67% decrease in tumor-free body mass by the end of the study. Preventive aliskiren administration (AP) significantly mitigated this loss, limiting it to just 12.42%. Interestingly, aliskiren also reduced tumor mass and volume, suggesting that the drug may interfere with the tumor's growth environment, possibly by dampening systemic inflammation.
Muscle Function and Survival
Functional improvements were equally notable. The AP group showed a 39.06% increase in grip strength and a 34.56% improvement in rotarod performance compared to the untreated CA group. Crucially, Kaplan-Meier analysis demonstrated that aliskiren treatment significantly extended the survival of tumor-bearing mice.
Molecular Mechanisms of Action
Aliskiren appears to act as a master regulator of muscle homeostasis. It suppressed the "muscle-wasting" genes Atrogin1 and MuRF1 and reduced the expression of autophagy markers. Furthermore, the drug acted as an oxidative stress shield, restoring levels of protective enzymes like SOD and Glutathione Peroxidase (GSH-Px) which are typically depleted during cancer-induced wasting. Systemic inflammation was also addressed, with serum levels of the pro-inflammatory cytokine IL-6 slashed by approximately 50% in the AP group.
Discussion
This study identifies aliskiren as a potent anti-cachexia agent that simultaneously targets RAS activation, systemic inflammation, oxidative stress, and the molecular pathways of protein degradation (ALP and UPP). A critical insight from the data is that timing is essential: the preventive (AP) group showed significantly more robust results than the therapeutic (AT) group, suggesting that early intervention—before the metabolic "point of no return"—is vital for effective cachexia management.
While these results in the C26 model are promising, limitations remain. Cancer cachexia in humans is highly heterogeneous, and metabolic drivers may vary between cancer types. Future research should focus on clinical translation, investigating the safety and efficacy of aliskiren in human patients, particularly those on complex chemotherapy regimens, and exploring potential synergistic effects with nutritional interventions.
Summary updated